The Induction of Antigen 85B-Specific CD8+ T Cells by Recombinant BCG Protects against Mycobacterial Infection in Mice. [PDF]
Komine-Aizawa S +5 more
europepmc +1 more source
Recombinant BCG expressing the LTAK63 adjuvant increased memory T cells and induced long-lasting protection against <i>Mycobacterium tuberculosis</i> challenge in mice. [PDF]
Marques-Neto LM +4 more
europepmc +1 more source
Recombinant BCG-LTAK63 Vaccine Candidate for Tuberculosis Induces an Inflammatory Profile in Human Macrophages. [PDF]
Dos Santos CC +8 more
europepmc +1 more source
[BCG vs. BCG plus recombinant alpha-interferon 2b in superficial tumors of the bladder].
BCG intravesical instillation is a well established therapy for superficial bladder carcinoma as adjuvant and/or prophylactic treatment. However side-effects are frequent when full doses are employed and therefore low dose alternative schedules were proposed.
E, Bercovich +3 more
openaire +1 more source
Recombinant BCG expressing the LTAK63 adjuvant improves a short-term chemotherapy schedule in the control of tuberculosis in mice. [PDF]
Trentini MM +6 more
europepmc +1 more source
Expression of recombinant antigen in BCG.
Little is known about the effect of different modes of expression of an antigen in rBCG on immune response. An appropriate wing of the immune system, with different degrees, is activated upon encounter with a foreign antigen. Knowledge of these responses is vital to the development of future recombinant vaccine. Various E.
openaire +1 more source
Recombinant BCG-Prime and DNA-Boost Immunization Confers Mice with Enhanced Protection against Mycobacterium kansasii. [PDF]
Komine-Aizawa S +5 more
europepmc +1 more source
The Diverse Applications of Recombinant BCG-Based Vaccines to Target Infectious Diseases Other Than Tuberculosis: An Overview. [PDF]
Mouhoub E, Domenech P, Ndao M, Reed MB.
europepmc +1 more source
Novel sequential treatment strategy for patients with muscle-invasive bladder cancer (MIBC): intravesical recombinant BCG, followed by neoadjuvant chemoimmunotherapy, radical cystectomy plus pelvic lymphadenectomy and adjuvant immunotherapy - protocol of a multicentre, single arm phase 2 trial (SAKK 06/19). [PDF]
Petrausch U +7 more
europepmc +1 more source
Mycobacterium bovis Wild-Type BCG or Recombinant BCG Secreting Murine IL-18 (rBCG/IL-18) Strains in Driving Immune Responses in Immunocompetent or Immunosuppressed Mice. [PDF]
Fol M +7 more
europepmc +1 more source

